{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:21Z","timestamp":1790959161702,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006955","name":"HHS|NIH|Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["K12\u2010CA133250\u201007"],"award-info":[{"award-number":["K12\u2010CA133250\u201007"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OSUCCC Pelotonia Idea Award"},{"name":"Eli Lilly Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"published-print":{"date-parts":[[2020,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>No approved therapy exists for cancer\u2010associated cachexia. The colon\u201026 mouse model of cancer cachexia mimics recent late\u2010stage clinical failures of anabolic anti\u2010cachexia therapy and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulator (SARM) GTx\u2010024. The histone deacetylase inhibitor (HDACi) AR\u201042 exhibited anti\u2010cachectic activity in this model. We explored combined SARM\/AR\u201042 therapy as an improved anti\u2010cachectic treatment paradigm. A reduced dose of AR\u201042 provided limited anti\u2010cachectic benefits, but, in combination with GTx\u2010024, significantly improved body weight, hindlimb muscle mass, and grip strength versus controls. AR\u201042 suppressed the IL\u20106\/GP130\/STAT3 signaling axis in muscle without impacting circulating cytokines. GTx\u2010024\u2010mediated \u03b2\u2010catenin target gene regulation was apparent in cachectic mice only when combined with AR\u201042. Our data suggest cachectic signaling in this model involves catabolic signaling insensitive to anabolic GTx\u2010024 therapy and a blockade of GTx\u2010024\u2010mediated anabolic signaling. AR\u201042 mitigates catabolic gene activation and restores anabolic responsiveness to GTx\u2010024. Combining GTx\u2010024, a clinically established anabolic therapy, with AR\u201042, a clinically evaluated HDACi, represents a promising approach to improve anabolic response in cachectic patients.<\/jats:p>","DOI":"10.15252\/emmm.201809910","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T03:30:35Z","timestamp":1578886235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor"],"prefix":"10.1038","volume":"12","author":[{"given":"Sophia G","family":"Liva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Chou","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees M","family":"Dauki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Sovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally E","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Chiu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Benedict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan C","family":"Remaily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moray","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii\u2010Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell A","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching\u2010Shih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-9190","authenticated-orcid":false,"given":"Christopher C","family":"Coss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"BFEMMM201809910_CR1","doi-asserted-by":"crossref","first-page":"13189","DOI":"10.1038\/s41598-017-10731-1","volume":"7","author":"CC Agley","year":"2017","unstructured":"Agley CC, Lewis FC, Jaka O, Lazarus NR, Velloso C, Francis\u2010West P, Ellison\u2010Hughes GM, Harridge SDR (2017) Active GSK3beta and an intact beta\u2010catenin TCF complex are essential for the differentiation of human myogenic progenitor cells. Sci Rep 7: 13189","journal-title":"Sci Rep"},{"key":"BFEMMM201809910_CR2","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1042\/BCJ20170032","volume":"474","author":"JM Argiles","year":"2017","unstructured":"Argiles JM, Lopez\u2010Soriano FJ, Stemmler B, Busquets S (2017) Novel targeted therapies for cancer cachexia. Biochem J 474: 2663\u20132678","journal-title":"Biochem J"},{"key":"BFEMMM201809910_CR3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2407-10-363","volume":"10","author":"P Aulino","year":"2010","unstructured":"Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F et\u00a0al (2010) Molecular, cellular and physiological characterization of the cancer cachexia\u2010inducing C26 colon carcinoma in mouse. BMC Cancer 10: 363","journal-title":"BMC Cancer"},{"key":"BFEMMM201809910_CR4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/SPC.0000000000000233","volume":"10","author":"R Ballaro","year":"2016","unstructured":"Ballaro R, Costelli P, Penna F (2016) Animal models for cancer cachexia. Curr Opin Support Palliat Care 10: 281\u2013287","journal-title":"Curr Opin Support Palliat Care"},{"key":"BFEMMM201809910_CR5","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH (2018) Cancer\u2010associated cachexia. Nat Rev Dis Primers 4: 17105","journal-title":"Nat Rev Dis Primers"},{"key":"BFEMMM201809910_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199607043350101","volume":"335","author":"S Bhasin","year":"1996","unstructured":"Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335: 1\u20137","journal-title":"N Engl J Med"},{"key":"BFEMMM201809910_CR7","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30: 2114\u20132120","journal-title":"Bioinformatics"},{"key":"BFEMMM201809910_CR8","doi-asserted-by":"crossref","first-page":"e22538","DOI":"10.1371\/journal.pone.0022538","volume":"6","author":"A Bonetto","year":"2011","unstructured":"Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA (2011) STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 6: e22538","journal-title":"PLoS One"},{"key":"BFEMMM201809910_CR9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jcsm.12023","volume":"6","author":"JA Chen","year":"2015","unstructured":"Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, Halder T, Zhang G, Li YP, Garcia JM (2015) Ghrelin prevents tumour\u2010 and cisplatin\u2010induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle 6: 132\u2013143","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"BFEMMM201809910_CR10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1208\/s12248-016-9876-3","volume":"18","author":"H Cheng","year":"2016","unstructured":"Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS et\u00a0al (2016) Preclinical pharmacokinetics study of R\u2010 and S\u2010Enantiomers of the histone deacetylase inhibitor, AR\u201042 (NSC 731438), in rodents. AAPS J 18: 737\u2013745","journal-title":"AAPS J"},{"key":"BFEMMM201809910_CR11","first-page":"2434","volume":"35","author":"TH Corbett","year":"1975","unstructured":"Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Can Res 35: 2434\u20132439","journal-title":"Can Res"},{"key":"BFEMMM201809910_CR12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/1008-682X.122339","volume":"16","author":"CC Coss","year":"2014","unstructured":"Coss CC, Jones A, Hancock ML, Steiner MS, Dalton JT (2014) Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian J Androl 16: 256\u2013261","journal-title":"Asian J Androl"},{"key":"BFEMMM201809910_CR13","first-page":"199","volume":"19","author":"J Crawford","year":"2016","unstructured":"Crawford J (2016) Clinical results in cachexia therapeutics. Curr Opin Clin Nutr Metab Care 19: 199\u2013204","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"BFEMMM201809910_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","volume":"18","author":"J Crawford","year":"2016","unstructured":"Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT (2016) Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep 18: 37","journal-title":"Curr Oncol Rep"},{"key":"BFEMMM201809910_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","volume":"2","author":"JT Dalton","year":"2011","unstructured":"Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS (2011) The selective androgen receptor modulator GTx\u2010024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double\u2010blind, placebo\u2010controlled phase II trial. J Cachexia Sarcopenia Muscle 2: 153\u2013161","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"BFEMMM201809910_CR16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","volume":"14","author":"AS Dobs","year":"2013","unstructured":"Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double\u2010blind, randomised controlled phase 2 trial. Lancet Oncol 14: 335\u2013345","journal-title":"Lancet Oncol"},{"key":"BFEMMM201809910_CR17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00018-011-0883-3","volume":"69","author":"V Dubois","year":"2012","unstructured":"Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F (2012) Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci 69: 1651\u20131667","journal-title":"Cell Mol Life Sci"},{"key":"BFEMMM201809910_CR18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jcsm.12083","volume":"6","author":"K Fearon","year":"2015","unstructured":"Fearon K, Argiles JM, Baracos VE, Bernabei R, Coats A, Crawford J, Deutz NE, Doehner W, Evans WJ, Ferrucci L et\u00a0al (2015) Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle 6: 272\u2013274","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"BFEMMM201809910_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1677\/JME-09-0048","volume":"44","author":"MA Gentile","year":"2010","unstructured":"Gentile MA, Nantermet PV, Vogel RL, Phillips R, Holder D, Hodor P, Cheng C, Dai H, Freedman LP, Ray WJ (2010) Androgen\u2010mediated improvement\u00a0of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of {beta}\u2010catenin. J Mol Endocrinol 44: 55\u201373","journal-title":"J Mol Endocrinol"},{"key":"BFEMMM201809910_CR20","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1074\/jbc.M113.517599","volume":"289","author":"R Glauben","year":"2014","unstructured":"Glauben R, Sonnenberg E, Wetzel M, Mascagni P, Siegmund B (2014) Histone deacetylase inhibitors modulate interleukin 6\u2010dependent CD4\u00a0+\u00a0T cell polarization in\u00a0vitro and in\u00a0vivo. J Biol Chem 289: 6142\u20136151","journal-title":"J Biol Chem"},{"key":"BFEMMM201809910_CR21","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.2147\/DDDT.S110131","volume":"11","author":"SA Graf","year":"2017","unstructured":"Graf SA, Garcia JM (2017) Anamorelin hydrochloride in the treatment of cancer anorexia\u2010cachexia syndrome: design, development, and potential place in therapy. Drug Des Devel Ther 11: 2325\u20132331","journal-title":"Drug Des Devel Ther"},{"key":"BFEMMM201809910_CR22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijcard.2014.10.026","volume":"184","author":"S von Haehling","year":"2015","unstructured":"von Haehling S, Anker SD (2015) Treatment of cachexia: an overview of recent developments. Int J Cardiol 184: 736\u2013742","journal-title":"Int J Cardiol"},{"key":"BFEMMM201809910_CR23","doi-asserted-by":"crossref","first-page":"8018197","DOI":"10.1155\/2017\/8018197","volume":"2017","author":"JP Hardee","year":"2017","unstructured":"Hardee JP, Montalvo RN, Carson JA (2017) Linking cancer cachexia\u2010induced anabolic resistance to skeletal muscle oxidative metabolism. Oxid Med Cell Longev 2017: 8018197","journal-title":"Oxid Med Cell Longev"},{"key":"BFEMMM201809910_CR24","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1172\/JCI68523","volume":"123","author":"WA He","year":"2013","unstructured":"He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas\u2010Ahner J, Wang J, Bloomston M, Muscarella P, Nau P et\u00a0al (2013) NF\u2010kappaB\u2010mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Investig 123: 4821\u20134835","journal-title":"J Clin Investig"},{"key":"BFEMMM201809910_CR25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/en.2008-0674","volume":"150","author":"A Jones","year":"2009","unstructured":"Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT (2009) Preclinical characterization of a (S)\u2010N\u2010(4\u2010cyano\u20103\u2010trifluoromethyl\u2010phenyl)\u20103\u2010(3\u2010fluoro, 4\u2010chlorophenoxy)\u20102\u2010hydroxy\u20102\u2010methyl\u2010propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology 150: 385\u2013395","journal-title":"Endocrinology"},{"key":"BFEMMM201809910_CR26","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1210\/en.2010-0150","volume":"151","author":"A Jones","year":"2010","unstructured":"Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT (2010) Effects of a novel selective androgen receptor modulator on dexamethasone\u2010induced and hypogonadism\u2010induced muscle atrophy. Endocrinology 151: 3706\u20133719","journal-title":"Endocrinology"},{"key":"BFEMMM201809910_CR27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2337\/db08-1293","volume":"58","author":"M Kelly","year":"2009","unstructured":"Kelly M, Gauthier MS, Saha AK, Ruderman NB (2009) Activation of AMP\u2010activated protein kinase by interleukin\u20106 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58: 1953\u20131960","journal-title":"Diabetes"},{"key":"BFEMMM201809910_CR28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0021-9258(18)48380-9","volume":"267","author":"JA Kemppainen","year":"1992","unstructured":"Kemppainen JA, Lane MV, Sar M, Wilson EM (1992) Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267: 968\u2013974","journal-title":"J Biol Chem"},{"key":"BFEMMM201809910_CR29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/jpet.105.088344","volume":"315","author":"J Kim","year":"2005","unstructured":"Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT (2005) The para substituent of S\u20103\u2010(phenoxy)\u20102\u2010hydroxy\u20102\u2010methyl\u2010N\u2010(4\u2010nitro\u20103\u2010trifluoromethyl\u2010phenyl)\u2010propionamid es is a major structural determinant of in\u00a0vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther 315: 230\u2013239","journal-title":"J Pharmacol Exp Ther"},{"key":"BFEMMM201809910_CR30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/00498254.2013.788233","volume":"43","author":"J Kim","year":"2013","unstructured":"Kim J, Wang R, Veverka KA, Dalton JT (2013) Absorption, distribution, metabolism and excretion of the novel SARM GTx\u2010024 [(S)\u2010N\u2010(4\u2010cyano\u20103\u2010(trifluoromethyl)phenyl)\u20103\u2010(4\u2010cyanophenoxy)\u20102\u2010hydroxy\u20102\u2010methylpropanamide] in rats. Xenobiotica 43: 993\u20131009","journal-title":"Xenobiotica"},{"key":"BFEMMM201809910_CR31","unstructured":"Kolde R (2015) pheatmap: Pretty Heatmaps."},{"key":"BFEMMM201809910_CR32","doi-asserted-by":"crossref","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","volume":"9","author":"M Lawrence","year":"2013","unstructured":"Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ (2013) Software for computing and annotating genomic ranges. PLoS Comput Biol 9: e1003118","journal-title":"PLoS Comput Biol"},{"key":"BFEMMM201809910_CR33","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S (2009) The sequence alignment\/Map format and SAMtools. Bioinformatics 25: 2078\u20132079","journal-title":"Bioinformatics"},{"key":"BFEMMM201809910_CR34","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao Y, Smyth GK, Shi W (2013) The Subread aligner: fast, accurate and scalable read mapping by seed\u2010and\u2010vote. Nucleic Acids Res 41: e108","journal-title":"Nucleic Acids Res"},{"key":"BFEMMM201809910_CR35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0303-7207(98)00105-1","volume":"142","author":"M Llovera","year":"1998","unstructured":"Llovera M, Garcia\u2010Martinez C, Lopez\u2010Soriano J, Carbo N, Agell N, Lopez\u2010Soriano FJ, Argiles JM (1998) Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 142: 183\u2013189","journal-title":"Mol Cell Endocrinol"},{"key":"BFEMMM201809910_CR36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA\u2010seq data with DESeq2. Genome Biol 15: 550","journal-title":"Genome Biol"},{"key":"BFEMMM201809910_CR37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","volume":"11","author":"RA Mesa","year":"2012","unstructured":"Mesa RA, Yasothan U, Kirkpatrick P (2012) Ruxolitinib. Nat Rev Drug Discov 11: 103\u2013104","journal-title":"Nat Rev Drug Discov"},{"key":"BFEMMM201809910_CR38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jcsm.12225","volume":"8","author":"KA Michaelis","year":"2017","unstructured":"Michaelis KA, Zhu X, Burfeind KG, Krasnow SM, Levasseur PR, Morgan TK, Marks DL (2017) Establishment and characterization of a novel murine model of pancreatic cancer cachexia. J Cachexia Sarcopenia Muscle 8: 824\u2013838","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"BFEMMM201809910_CR39","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1021\/jm900280m","volume":"52","author":"ML Mohler","year":"2009","unstructured":"Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD (2009) Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 52: 3597\u20133617","journal-title":"J Med Chem"},{"key":"BFEMMM201809910_CR40","first-page":"8066","volume":"14","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Aikawa K, Hara T, Yamaoka M (2017) Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models. Oncol Lett 14: 8066\u20138071","journal-title":"Oncol Lett"},{"key":"BFEMMM201809910_CR41","doi-asserted-by":"crossref","first-page":"e103202","DOI":"10.1371\/journal.pone.0103202","volume":"9","author":"R Narayanan","year":"2014","unstructured":"Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS, Dalton JT (2014) Selective androgen receptor modulators (SARMs) negatively regulate triple\u2010negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One 9: e103202","journal-title":"PLoS One"},{"key":"BFEMMM201809910_CR42","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-72185-4","volume-title":"Testosterone: action, deficiency, substitution","author":"E Nieschlag","year":"1998","unstructured":"Nieschlag E, Behre HM (Eds.) (1998) Testosterone: action, deficiency, substitution, 2 edn. Berlin, Heidelberg: Springer","edition":"2 edn"},{"key":"BFEMMM201809910_CR43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00003495-200464070-00004","volume":"64","author":"R Orr","year":"2004","unstructured":"Orr R, Fiatarone Singh M (2004) The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 64: 725\u2013750","journal-title":"Drugs"},{"key":"BFEMMM201809910_CR44","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1242\/jcs.026534","volume":"121","author":"A Otto","year":"2008","unstructured":"Otto A, Schmidt C, Luke G, Allen S, Valasek P, Muntoni F, Lawrence\u2010Watt D, Patel K (2008) Canonical Wnt signalling induces satellite\u2010cell proliferation during adult skeletal muscle regeneration. J Cell Sci 121: 2939\u20132950","journal-title":"J Cell Sci"},{"key":"BFEMMM201809910_CR45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semcdb.2015.09.002","volume":"54","author":"F Penna","year":"2016","unstructured":"Penna F, Busquets S, Argiles JM (2016) Experimental cancer cachexia: evolving strategies for getting closer to the human scenario. Semin Cell Dev Biol 54: 20\u201327","journal-title":"Semin Cell Dev Biol"},{"key":"BFEMMM201809910_CR46","doi-asserted-by":"crossref","first-page":"18431","DOI":"10.1016\/S0021-9258(18)55078-X","volume":"266","author":"RP Rehfuss","year":"1991","unstructured":"Rehfuss RP, Walton KM, Loriaux MM, Goodman RH (1991) The cAMP\u2010regulated enhancer\u2010binding protein ATF\u20101 activates transcription in response to cAMP\u2010dependent protein kinase A. J Biol Chem 266: 18431\u201318434","journal-title":"J Biol Chem"},{"key":"BFEMMM201809910_CR47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139\u2013140","journal-title":"Bioinformatics"},{"key":"BFEMMM201809910_CR48","first-page":"1","volume-title":"Testosterone: Action \u2010 Deficiency \u2010 Substitution","author":"FFG Rommerts","year":"1998","unstructured":"Rommerts FFG (1998) Testosterone: an overview of biosynthesis, transport, metabolism and nongenomic actions. In Testosterone: Action \u2010 Deficiency \u2010 Substitution, Nieschlag E, Behre HM (eds), pp 1\u201331. Berlin, Heidelberg: Springer Berlin Heidelberg"},{"key":"BFEMMM201809910_CR49","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.celrep.2016.04.022","volume":"15","author":"A Rudolf","year":"2016","unstructured":"Rudolf A, Schirwis E, Giordani L, Parisi A, Lepper C, Taketo MM, Le Grand F (2016) beta\u2010Catenin activation in muscle progenitor cells regulates tissue repair. Cell Rep 15: 1277\u20131290","journal-title":"Cell Rep"},{"key":"BFEMMM201809910_CR50","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","volume":"58","author":"DW Sborov","year":"2017","unstructured":"Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z et\u00a0al (2017) A phase 1 trial of the HDAC inhibitor AR\u201042 in patients with multiple myeloma and T\u2010 and B\u2010cell lymphomas. Leuk Lymphoma 58: 2310\u20132318","journal-title":"Leuk Lymphoma"},{"key":"BFEMMM201809910_CR51","doi-asserted-by":"crossref","first-page":"17054","DOI":"10.1074\/jbc.M109.099002","volume":"285","author":"A Schmidt","year":"2010","unstructured":"Schmidt A, Kimmel DB, Bai C, Scafonas A, Rutledge S, Vogel RL, McElwee\u2010Witmer S, Chen F, Nantermet PV, Kasparcova V et\u00a0al (2010) Discovery of the selective androgen receptor modulator MK\u20100773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem 285: 17054\u201317064","journal-title":"J Biol Chem"},{"key":"BFEMMM201809910_CR52","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1210\/en.2013-1004","volume":"154","author":"C Serra","year":"2013","unstructured":"Serra C, Sandor NL, Jang H, Lee D, Toraldo G, Guarneri T, Wong S, Zhang A, Guo W, Jasuja R et\u00a0al (2013) The effects of testosterone deprivation and supplementation on proteasomal and autophagy activity in the skeletal muscle of the male mouse: differential effects on high\u2010androgen responder and low\u2010androgen responder muscle groups. Endocrinology 154: 4594\u20134606","journal-title":"Endocrinology"},{"key":"BFEMMM201809910_CR53","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.1074\/jbc.M115.638411","volume":"290","author":"DN Seto","year":"2015","unstructured":"Seto DN, Kandarian SC, Jackman RW (2015) A key role for leukemia inhibitory factor in c26 cancer cachexia. J Biol Chem 290: 19976\u201319986\u00a0\u00a0","journal-title":"J Biol Chem"},{"key":"BFEMMM201809910_CR54","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1073\/pnas.96.10.5522","volume":"96","author":"M Shtutman","year":"1999","unstructured":"Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben\u2010Ze'ev A (1999) The cyclin D1 gene is a target of the beta\u2010catenin\/LEF\u20101 pathway. Proc Natl Acad Sci USA 96: 5522\u20135527","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201809910_CR55","doi-asserted-by":"crossref","first-page":"11177","DOI":"10.1074\/jbc.M115.641514","volume":"290","author":"KA Silva","year":"2015","unstructured":"Silva KA, Dong J, Dong Y, Dong Y, Schor N, Tweardy DJ, Zhang L, Mitch WE (2015) Inhibition of Stat3 activation suppresses caspase\u20103 and the ubiquitin\u2010proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem 290: 11177\u201311187","journal-title":"J Biol Chem"},{"key":"BFEMMM201809910_CR56","doi-asserted-by":"crossref","first-page":"e0181125","DOI":"10.1371\/journal.pone.0181125","volume":"12","author":"EM Silva","year":"2017","unstructured":"Silva EM, Mariano VS, Pastrez PRA, Pinto MC, Castro AG, Syrjanen KJ, Longatto\u2010Filho A (2017) High systemic IL\u20106 is associated with worse prognosis in patients with non\u2010small cell lung cancer. PLoS One 12: e0181125","journal-title":"PLoS One"},{"key":"BFEMMM201809910_CR57","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1210\/en.2003-0741","volume":"144","author":"R Singh","year":"2003","unstructured":"Singh R, Artaza JN, Taylor WE, Gonzalez\u2010Cadavid NF, Bhasin S (2003) Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1\/2 pluripotent cells through an androgen receptor\u2010mediated pathway. Endocrinology 144: 5081\u20135088","journal-title":"Endocrinology"},{"key":"BFEMMM201809910_CR58","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1210\/en.2008-0858","volume":"150","author":"R Singh","year":"2009","unstructured":"Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R (2009) Regulation of myogenic differentiation by androgens: cross talk between androgen receptor\/beta\u2010catenin and follistatin\/transforming growth factor\u2010beta signaling pathways. Endocrinology 150: 1259\u20131268","journal-title":"Endocrinology"},{"key":"BFEMMM201809910_CR59","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.1152\/ajpendo.00370.2002","volume":"285","author":"I Sinha\u2010Hikim","year":"2003","unstructured":"Sinha\u2010Hikim I, Roth SM, Lee MI, Bhasin S (2003) Testosterone\u2010induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab 285: E197\u2013E205","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BFEMMM201809910_CR60","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/fon.13.273","volume":"10","author":"R Srinath","year":"2014","unstructured":"Srinath R, Dobs A (2014) Enobosarm (GTx\u2010024, S\u201022): a potential treatment for cachexia. Future Oncol 10: 187\u2013194","journal-title":"Future Oncol"},{"key":"BFEMMM201809910_CR61","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et\u00a0al (2005) Gene set enrichment analysis: a knowledge\u2010based approach for interpreting genome\u2010wide expression profiles. Proc Natl Acad Sci USA 102: 15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFEMMM201809910_CR62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13539-014-0141-2","volume":"5","author":"EE Talbert","year":"2014","unstructured":"Talbert EE, Metzger GA, He WA, Guttridge DC (2014) Modeling human cancer cachexia in colon 26 tumor\u2010bearing adult mice. J Cachexia Sarcopenia Muscle 5: 321\u2013328","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"BFEMMM201809910_CR63","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non\u2010small\u2010cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double\u2010blind, phase 3 trials. Lancet Oncol 17: 519\u2013531","journal-title":"Lancet Oncol"},{"key":"BFEMMM201809910_CR64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89: 381\u2013410","journal-title":"Physiol Rev"},{"key":"BFEMMM201809910_CR65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jcsm.12035","volume":"7","author":"M Toledo","year":"2016","unstructured":"Toledo M, Penna F, Oliva F, Luque M, Betancourt A, Marmonti E, Lopez\u2010Soriano FJ, Argiles JM, Busquets S (2016) A multifactorial anti\u2010cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. J Cachexia Sarcopenia Muscle 7: 48\u201359","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"BFEMMM201809910_CR66","doi-asserted-by":"crossref","first-page":"djv274","DOI":"10.1093\/jnci\/djv274","volume":"107","author":"YC Tseng","year":"2015","unstructured":"Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB et\u00a0al (2015a) Preclinical investigation of the novel histone deacetylase inhibitor AR\u201042 in the treatment of cancer\u2010induced cachexia. J Natl Cancer Inst 107: djv274","journal-title":"J Natl Cancer Inst"},{"key":"BFEMMM201809910_CR100","unstructured":"Tseng Y, Kulp SK, Lai I, Hsu E, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB et\u00a0al (2015b) Gene Expression Omnibus GSE65936 (https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE65936). [DATASET]"},{"key":"BFEMMM201809910_CR67","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(10)70021-8","volume":"11","author":"A Vigano","year":"2010","unstructured":"Vigano A, Piccioni M, Trutschnigg B, Hornby L, Chaudhury P, Kilgour R (2010) Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol 11: 679\u2013684","journal-title":"Lancet Oncol"},{"key":"BFEMMM201809910_CR68","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.mce.2012.10.019","volume":"365","author":"JP White","year":"2013","unstructured":"White JP, Gao S, Puppa MJ, Sato S, Welle SL, Carson JA (2013a) Testosterone regulation of Akt\/mTORC1\/FoxO3a signaling in skeletal muscle. Mol Cell Endocrinol 365: 174\u2013186","journal-title":"Mol Cell Endocrinol"},{"key":"BFEMMM201809910_CR69","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1242\/bio.20136544","volume":"2","author":"JP White","year":"2013","unstructured":"White JP, Puppa MJ, Narsale A, Carson JA (2013b) Characterization of the male ApcMin\/+ mouse as a hypogonadism model related to cancer cachexia. Biol Open 2: 1346\u20131353","journal-title":"Biol Open"},{"key":"BFEMMM201809910_CR70","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2307\/2532694","volume":"48","author":"SP Wright","year":"1992","unstructured":"Wright SP (1992) Adjusted P\u2010values for simultaneous inference. Biometrics 48: 1005\u20131013","journal-title":"Biometrics"},{"key":"BFEMMM201809910_CR71","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.25660","volume":"129","author":"S Zhang","year":"2011","unstructured":"Zhang S, Suvannasankha A, Crean CD, White VL, Chen CS, Farag SS (2011) The novel histone deacetylase inhibitor, AR\u201042, inhibits gp130\/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells. Int J Cancer 129: 204\u2013213","journal-title":"Int J Cancer"},{"key":"BFEMMM201809910_CR101","unstructured":"Zimmers TA, Aydogdu T, Koniaris LG, Guttridge DC, Khuri S, Kunzevitzky N (2011) Gene Expression Omnibus GSE24112 (https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?token=bpyvjkkekkwswxk&acc=GSE24112). [DATASET]"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201809910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.15252\/emmm.201809910","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.15252\/emmm.201809910\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.embopress.org\/doi\/pdf\/10.15252\/emmm.201809910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.15252\/emmm.201809910.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:29:35Z","timestamp":1779085775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.15252\/emmm.201809910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,7]]}},"alternative-id":["BFEMMM201809910"],"URL":"https:\/\/doi.org\/10.15252\/emmm.201809910","relation":{},"ISSN":["1757-4676","1757-4684"],"issn-type":[{"value":"1757-4676","type":"print"},{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"14 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u2010S. Chen is an inventor of AR\u201042, which was licensed to Recursion Pharmaceuticals, Inc., for clinical development by The Ohio State University Research Foundation. C.C. Coss is a former employee of GTx, Inc., owner of GTx\u2010024, but has no financial relationship with or any equity in GTx, Inc. Recursion Pharmaceuticals, Inc. and GTx, Inc. were not involved in any way with the financing, design, or interpretation of the reported studies. All other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"EMMM201809910"}}